BioCentury | Dec 20, 2019
Targets & Mechanisms

Controlling T cells via epigenetics

An international academic team has discovered an epigenetic pathway that regulates CD4 + T cell differentiation and activity, and could yield new therapeutic targets for autoimmunity. As drug developers seek the next generation of targeted...
BioCentury | Nov 28, 2018
Emerging Company Profile

Cybrexa: pH-based tumor targeting

Cybrexa Therapeutics Inc. is developing a targeting technology that taps the pH of the tumor microenvironment to enhance the delivery specificity and decrease the toxicity of small molecule cancer therapies, starting with PARP inhibitors. Cybrexa...
BioCentury | Feb 21, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Epigenetic, methyllysine-binding protein inhibitors Identification of the first potent and selective inhibitor of a methyllysine-binding domain suggests this class of epigenetic...
BioCentury | Oct 22, 2012
Clinical News

Ersatta: Phase Ib/IIa data

Top-line data from 42 Type I diabetics with signs of peripheral neuropathy in the Phase IIa portion of a double-blind, U.S. Phase Ib/IIa trial showed that subcutaneous Ersatta significantly improved mean sural SNCV from baseline...
BioCentury | Jun 18, 2012
Clinical News

Ersatta: Phase Ib data

A double-blind, placebo-controlled, U.S. Phase Ib trial in 30 Type I diabetics showed that multiple doses of 0.3, 1 and 3.3 mg subcutaneous Ersatta were well tolerated with no serious adverse events reported. Data were...
BioCentury | Jul 4, 2011
Clinical News

Cebix preclinical data

In a rat model of diabetic peripheral neuropathy, subcutaneous Ersatta led to a 4 m/sec reversal of sensory nerve conduction velocity impairment. The long-acting form of C-peptide is in Phase Ib testing to treat Type...
BioCentury | Jun 20, 2011
Clinical News

Ersatta: Phase Ib started

Cebix began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate single and multiple subcutaneous injections of Ersatta in up to 60 Type I diabetics. Cebix Inc. , La Jolla, Calif. Product: Ersatta ( CBX129801 ) Business: Endocrine...
BioCentury | Oct 6, 2003
Clinical News

Cytovaxine: Phase I

Cytovax Biotechnologies Inc. (TSE:CBX), Edmonton, Alberta Product: Cytovaxine Business: Infectious Molecular target: NA Description: Peptide vaccine derived from the Pseudomonas aeruginosa pilin protein Standard indication: Pseudomonas Indication: Treat P. aeruginosa infection Endpoint: Safety and immunogenicity...
BioCentury | Oct 7, 2002
Clinical News

Cytovaxine: Phase I

Cytovax Biotechnologies Inc. (TSE:CBX), Edmonton, Alberta Product: Cytovaxine Business: Infectious diseases Therapeutic category: Vaccine Target: Immune cells Description: Peptide vaccine derived from the Pseudomonas aeruginosa pilin protein Indication: Treat P. aeruginosa infection Endpoint: Safety and...
BioCentury | Apr 8, 2002
Clinical News

Cytovaxine: CBX began a double-blind, dose-escalation Canadian Phase I trial in 35 healthy volunteers. Shire Pharmaceuticals Group plc (LSE:SHP, SHPGY, Basingst

Cytovax Biotechnologies Inc. (TSE:CBX), Edmonton, Alberta Product: Cytovaxine Business: Infectious diseases Therapeutic category: Vaccine Target: Immune cells Description: Peptide vaccine derived from the Pseudomonas aeruginosa pilin protein Indication: Treat P. aeruginosa infection Endpoint: Safety and...
Items per page:
1 - 10 of 15